194473-04-6Relevant articles and documents
Method for preparing quinazolone and derivatives thereof by using chitosan-loaded copper catalyst
-
Paragraph 0108-0114, (2021/05/12)
The invention discloses a method for preparing quinazolone and derivatives thereof by using a chitosan-loaded copper catalyst, which comprises the following steps of replacing residual gas in a reaction container with inert gas, adding a catalytic amount of copper ion-loaded chitosan catalyst, substituted 2-halogenated benzoic acid, substituted amidine hydrochloride, inorganic alkali and a mixed solvent into the reaction container, and heating for reaction, after the reaction time is 2-18 hours, extracting the product by using ethyl acetate, filtering and recovering the copper ion-loaded chitosan catalyst, concentrating the filtrate under reduced pressure, and purifying the product by column chromatography. The method has the advantages of low catalyst dosage, recoverability, easy separation after reaction, no metal residue, simple post-treatment, and suitableness for large-scale production.
Quinazolinone compounds and application in preparing drug for preventing agricultural plant diseases
-
Paragraph 0020-0024; 0029-0032, (2019/11/25)
The invention discloses application of quinazolinone compounds KZL-01-KZL-34 in preventing or resisting agricultural plant fungal diseases. Antimicrobial activity testing results show that the compounds have inhibition activity on the plant fungal diseases caused by sclerotinia sclerotiorum, rhizoctonia solani, fusarium graminearum Sehw. and botrytis cinerea, and especially have higher inhibitionactivity on the rhizoctonia solani, the inhibition activity of part of the compounds on the germs is higher than that of azoxystrobin, and the quinazolinone compounds can be used as lead compounds ofan agricultural fungicide to be developed.
STYRYL QUINAZOLINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE AGENTS
-
Page/Page column 8, (2015/02/25)
The present invention relates to styryl quinazoline derivatives of the general formula (I) and pharmaceutically acceptable solvates, hydrates, salts, regioisomeric and polymorphic forms thereof as well as pharmaceutical compositions containing at least on